Treatment of acne using A 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: A randomized controlled trial

Obstetrics and Gynecology

Volumn 112, Issue 4, 2008, Pages 773-781

  Maloney, J Michael ^a   Dietze, Peter ^b   Watson, David ^b   Niknian, Minoo ^b   Lee Rugh, Sooji ^b   Sampson Landers, Carole ^b   Korner, Paul ^b  

^a Cherry Creek Research Inc   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; PLACEBO; ANDROSTANE DERIVATIVE; DROSPIRENONE; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERKALEMIA; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENORRHAGIA; MENSTRUATION DISORDER; METRORRHAGIA; MULTIPLE CYCLE TREATMENT; NAUSEA; ORAL CONTRACEPTION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; THROMBOEMBOLISM; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ACNE VULGARIS; ADOLESCENT; ADULT; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; DOUBLE-BLIND METHOD; ETHINYL ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 55449126686     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e318187e1c5     Document Type: Article

References (15)

1. Gollnick H. Current concepts of the pathogenesis of acne: implications for drug treatment. Drugs 2003;63:1579-96.
2. Redmond GP, Olson WH, LippmanJS, Kafrissen ME, Jones TM, Jorizzo JL. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997;89:615-22.
3. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002;69:2-15.
4. Thorneycroft IH, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004;74:123-30.
5. Klipping C, MarrJ. Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005;71:409-16.
6. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62: 29-38.
7. FoidartJM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel [published erratum appears in Eur J Contracept Reprod Health Care 2001;6: 63]. Eur J Contracept Reprod Health Care 2000;5:124-34.
8. Oelkers W, Berger V, Bolik A, Bahr V, Hazard B, Beier S, et al. Dihydrospirorenone, a new progestogen with antiminer-alocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 1991;73:837-42.
9. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492-501.
10. Bachmann G, Sulak PJ, Sampson-Landers C, Benda N, MarrJ. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone. Contraception 2004;70:191-8.
11. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new dro-spirenone-containing oral contraceptive formulation. Contraception 2005;72:414-21.
12. Koltun W, Lucky AW, Thiboutot D, Niknian M, Sampson-Landers C, Korner P, Marr J. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 2008;77:249-56.
13. Leyden J, Shalita A, Hordinsky M, Swinyer L, Stanczyk FZ, Weber ME. Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial. J Am Acad Dermatol 2002;47:399-409.
14. Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997;37:746-54.
15. Thiboutot D, Archer DF, Lemay A, Washenik K, Roberts J, Harrison DD. A randomized, controlled trial of a low-dose contraceptive containing 20 μg of ethinyl estradiol and 100 μg of levonorgestrel for acne treatment. 2001;76: 461-8.